# Phase 2 Carcinoma, Non-Small-Cell Lung trials: 433 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 433 trials in phase 2 for Carcinoma, Non-Small-Cell Lung that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Carcinoma, Non-Small-Cell Lung trials: 433 rows for $21.65, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 13 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/carcinoma-non-small-cell-lung

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 433
- Recruiting or not yet: 433
- Read on: November 19, 2026

## Trials

The 25 newest of 433, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946848 | Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC. | Immuneering Corporation | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946848) |
| November 18, 2026 | NCT07944313 | Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung... | Quanzhou First Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Carcinoma of Lung | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944313) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 13, 2026 | NCT07936578 | Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Guizhou Medical University | Phase 2 | Not yet recruiting | Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936578) |
| November 13, 2026 | NCT07936422 | A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients | Centre Leon Berard | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer, Pan-rare Tumor With no T-DXd Approvals, Pan-frequent... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936422) |
| November 5, 2026 | NCT07919691 | Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy | Ruijin Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919691) |
| November 5, 2026 | NCT07917767 | A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of... | Tang-Du Hospital | Phase 2 | Not yet recruiting | NSCLC Stage IIIA/B, NSCLC Stage II | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917767) |
| November 2, 2026 | NCT07911449 | Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases | Cho Ray Hospital | Phase 2 | Recruiting | Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Activating Mutation | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911449) |
| October 26, 2026 | NCT07894367 | Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein... | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894367) |
| October 22, 2026 | NCT07890636 | Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC | Ruijin Hospital | Phase 2 | Not yet recruiting | Lung Neoplasm Malignant | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890636) |
| October 22, 2026 | NCT07890493 | Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer | Canadian Cancer Trials Group | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890493) |
| October 21, 2026 | NCT07885709 | MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC | Peking University People's Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer (NSCLC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885709) |
| October 20, 2026 | NCT07882940 | Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC | Sun Yat-sen University | Phase 2 | Not yet recruiting | Non-Small Cell Carcinoma of Lung, Locally Advanced | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882940) |
| October 15, 2026 | NCT07875465 | Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic, Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875465) |
| October 15, 2026 | NCT07874984 | SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874984) |
| October 15, 2026 | NCT07874490 | Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC | NYU Langone Health | Phase 2 | Recruiting | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874490) |
| October 14, 2026 | NCT07874464 | Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC) | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874464) |
| October 13, 2026 | NCT07871214 | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage... | Bristol-Myers Squibb | Phase 2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871214) |
| October 7, 2026 | NCT07863167 | An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Non-small Cell Lung Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863167) |
| October 2, 2026 | NCT07855965 | Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for... | West China Hospital | Phase 2 | Recruiting | Carcinoma, Non-Small-Cell Lung (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855965) |
| September 29, 2026 | NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848243) |
| September 29, 2026 | NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845916) |
| September 25, 2026 | NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC | Guangdong Provincial People's Hospital | Phase 2 | Not yet recruiting | NSCLC (Non-small Cell Lung Carcinoma) | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842471) |
| September 25, 2026 | NCT07841106 | Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases | Jiangmen Central Hospital | Phase 2 | Not yet recruiting | Lung Cancer (Non-Small Cell), Radiation, Brain Injury, Brain Edema, Brain Necrosis | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841106) |
| September 23, 2026 | NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836543) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 23 |
| Shanghai Pulmonary Hospital, Shanghai, China | 16 |
| Tianjin Medical University Cancer Institute and Hospital | 13 |
| Hunan Province Tumor Hospital | 12 |
| Fudan University | 9 |
| Peking University Cancer Hospital & Institute | 8 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 7 |
| Memorial Sloan Kettering Cancer Center | 6 |
| Sichuan University | 6 |
| City of Hope Medical Center | 5 |
| Guangdong Provincial People's Hospital | 5 |
| Fundación GECP | 5 |
| Peking Union Medical College Hospital | 4 |
| Anhui Provincial Cancer Hospital | 4 |
| Guangdong Association of Clinical Trials | 4 |
| University Health Network, Toronto | 4 |
| [Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-kelun-biotech-biopharmaceutical-co-ltd) | 4 |
| Tang-Du Hospital | 4 |
| University of Washington | 4 |
| SWOG Cancer Research Network | 4 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 3 |
| Hunan Cancer Hospital | 3 |
| National Cancer Institute (NCI) | 3 |
| Liaoning Cancer Hospital & Institute | 3 |
| Wake Forest University Health Sciences | 3 |

## By country

| Country | Trials |
| --- | --- |
| China | 208 |
| United States | 107 |
| Spain | 25 |
| France | 23 |
| Italy | 17 |
| Germany | 16 |
| South Korea | 16 |
| Canada | 16 |
| Australia | 15 |
| Taiwan | 14 |
| Japan | 10 |
| Netherlands | 10 |
| United Kingdom | 10 |
| Poland | 8 |
| Brazil | 8 |
| Belgium | 7 |
| Israel | 7 |
| Hungary | 5 |
| Singapore | 5 |
| Hong Kong | 5 |
| Switzerland | 5 |
| Turkey (Türkiye) | 5 |
| Greece | 4 |
| Ireland | 3 |
| Argentina | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Masonry and concrete contractors in the United States](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/united-states)
- [Malaysian restaurants in the United States](https://specstream.ai/data/businesses/malaysian-restaurants/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
- [Litigation law firms in the United States](https://specstream.ai/data/businesses/litigation-law-firms/united-states)
- [Lebanese restaurants in the United States](https://specstream.ai/data/businesses/lebanese-restaurants/united-states)
- [Latin American restaurants in the United States](https://specstream.ai/data/businesses/latin-american-restaurants/united-states)
